Prognostic significance of c-Met, β-catenin and FAK in patients with hepatocellular carcinoma following surgery

被引:12
|
作者
Gong, Xue-Yi [1 ]
Ma, Ning [2 ]
Xu, Hong-Xu [3 ]
Chen, Fan [2 ]
Huang, Xiao-Hui [2 ]
Wang, Qian [1 ]
机构
[1] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Hepatobiliary Surg, 58 2nd Yat Sen Rd, Guangzhou 510080, Guangdong, Peoples R China
[2] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Gen Surg Lab, 58 2nd Yat Sen Rd, Guangzhou 510080, Guangdong, Peoples R China
[3] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Lab Med, Guangzhou 510080, Guangdong, Peoples R China
基金
中国国家自然科学基金;
关键词
hepatocyte growth factor receptor; beta-catenin; focal adhesion kinase; prognostic; hepatocellular carcinoma; FOCAL ADHESION KINASE; MOLECULAR-MECHANISMS; TARGETED THERAPIES; SOMATIC MUTATIONS; CANCER; EXPRESSION; PROGRESSION; DOMAIN; LIVER; PATHWAYS;
D O I
10.3892/ol.2018.7733
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The present study aimed to investigate the prognostic value of specific molecular markers in patients with hepatocellular carcinoma (HCC) who had received surgery. Immunohistochemical analysis was used to measure the expression of hepatocyte growth factor receptor (c-Met), beta-catenin and focal adhesion kinase (FAK) in patients with HCC. c-Met expression was identified to be high in patients with larger tumors, higher alpha-fetoprotein (AFP) levels, higher Edmondson grades, portal vein invasion and higher tumor-node-metastasis (TNM) stages. FAK expression was high in patients with portal vein invasion, higher Edmondson grades and higher TNM stages. beta-catenin expression was high in patients with larger tumors, hepatitis B virus (HBV) infection, portal vein invasion, higher Edmondson grades and higher TNM stages. Following multivariate analysis, FAK (P=0.002) and beta-catenin (P=0.006) expression levels were demonstrated to be significantly associated with Edmondson grade. Additionally, the tumor size (P=0.009) and HBV infection status (P=0.002) were revealed to be associated with beta-catenin expression. Kaplan-Meier survival curve analysis demonstrated that patients with HCC with higher FAK expression, higher beta-catenin expression, portal vein invasion, higher Edmondson grades, higher TNM stages, younger ages and higher AFP levels had significantly poorer prognoses. Cox's regression analysis revealed that the survival period was correlated with the Edmondson grade, age, AFP level, and FAK and beta-catenin expression. Univariate analysis of c-Met, beta-catenin and FAK identified a significant correlation between FAK and beta-catenin (P=0.015). Correlation analysis revealed no significant correlation between the three molecular markers, but beta-catenin and c-Met were markedly correlated (P=0.052). No significant correlation between FAK, c-Met or beta-catenin expression was identified. FAK and beta-catenin expression demonstrated a correlation with a range of clinicopathological factors, and high FAK and beta-catenin expression levels were identified to be correlated with a poor survival rate of patients with HCC. Thus, patients with higher FAK and beta-catenin expression may require more aggressive therapy. The results of the present study suggest that FAK and beta-catenin expression possess more prognostic value than c-Met expression in patients with HCC.
引用
收藏
页码:3796 / 3805
页数:10
相关论文
共 50 条
  • [1] FAK Is Required for c-Met/β-Catenin-Driven Hepatocarcinogenesis
    Shang, Na
    Arteaga, Maribel
    Zaidi, Ali
    Stauffer, Jimmy
    Cotler, Scott J.
    Zeleznik-Le, Nancy J.
    Zhang, Jiwang
    Qiu, Wei
    HEPATOLOGY, 2015, 61 (01) : 214 - 226
  • [2] FAK is required for c-Met/β-catenin-driven hepatocarcinogenesis
    Shang, Na
    Arteaga, Maribel
    Stauffer, Jimmy
    Cotler, Scott
    Zhang, Jiwang
    Qiu, Wei
    HEPATOLOGY, 2014, 60 : 652A - 652A
  • [3] C-MET EXPRESSION AND RECURRENCE FOLLOWING SURGICAL RESECTION OF HEPATOCELLULAR CARCINOMA
    Hashimoto, Jun
    Kondo, Shunsuke
    Hagihara, Atsushi
    Morizane, Chigusa
    Ueno, Hideki
    Tamura, Kenji
    Kanai, Yae
    Tsuda, Hitoshi
    Okusaka, Takuji
    Ojima, Hidenori
    ANNALS OF ONCOLOGY, 2010, 21 : 19 - 20
  • [4] Prognostic Significance of c-Met Expression in Glioblastomas
    Kong, Doo-Sik
    Song, Sang-Yong
    Kim, Duk-Hwan
    Joo, Kyeung Min
    Yoo, Jin-San
    Koh, Jong Sung
    Dong, Seung Myung
    Suh, Yeon-Lim
    Lee, Jung-Il
    Park, Kwan
    Kim, Jong Hyun
    Nam, Do-Hyun
    CANCER, 2009, 115 (01) : 140 - 148
  • [5] C-MET OVEREXPRESSION IN HEPATOCELLULAR-CARCINOMA
    SUZUKI, K
    HAYASHI, N
    YAMADA, Y
    ITO, T
    MIYAMOTO, Y
    FUSAMOTO, H
    KAMADA, T
    HEPATOLOGY, 1993, 18 (04) : A155 - A155
  • [6] A Survey of c-MET Expression and Amplification in 287 Patients with Hepatocellular Carcinoma
    Lee, Su Jin
    Lee, Jeeyun
    Sohn, Insuk
    Mao, Mao
    Kai, Wang
    Park, Cheol-Keun
    Lim, Ho Yeong
    ANTICANCER RESEARCH, 2013, 33 (11) : 5179 - 5186
  • [7] Dynasore potentiates c-Met inhibitors against hepatocellular carcinoma through destabilizing c-Met
    Zaky, Mohamed Y.
    Liu, Xiuxiu
    Wang, Taishu
    Wang, Shanshan
    Liu, Fang
    Wang, Duchuang
    Wu, Yueguang
    Zhang, Yang
    Guo, Dong
    Sun, Qianhui
    Li, Qiong
    Zhang, Jinrui
    Zhang, Yingqiu
    Dong, Weijie
    Liu, Zhenhua
    Liu, Shuyan
    Liu, Han
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2020, 680
  • [8] Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma
    M Miyamoto
    H Ojima
    M Iwasaki
    H Shimizu
    A Kokubu
    N Hiraoka
    T Kosuge
    D Yoshikawa
    T Kono
    H Furukawa
    T Shibata
    British Journal of Cancer, 2011, 105 : 131 - 138
  • [9] Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma
    Miyamoto, M.
    Ojima, H.
    Iwasaki, M.
    Shimizu, H.
    Kokubu, A.
    Hiraoka, N.
    Kosuge, T.
    Yoshikawa, D.
    Kono, T.
    Furukawa, H.
    Shibata, T.
    BRITISH JOURNAL OF CANCER, 2011, 105 (01) : 131 - 138
  • [10] Significance of PD-L1 clones and C-MET expression in hepatocellular carcinoma
    Chun, Hyung-Wook
    Hong, Ran
    ONCOLOGY LETTERS, 2019, 17 (06) : 5487 - 5498